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T lymphocyte interactions with target and antigen presenting cells appear to
require an ensemble of T lymphocyte surface proteins: the antigen receptor-
CD3 (T3) complex, and the accessory molecules CD4, CD8, LFA-1, and CD2
(1). Target cells and antigen-presenting cells also express an array of accessory
molecules, such as MHC antigens, LFA-3, and ICAM-1 (1). Although it is
hypothesized that accessory molecules on T lymphocytes interact with molecules
on other cells to mediate intercellular adhesion, there has been little direct
evidence for this. However, recent studies on CD2 have suggested that it interacts
with a cell surface molecule termed lymphocyte function-associated molecule 3
(LFA-3).'
CD2 (T11, LFA-2, E receptor) is a 50,000 M, T lymphocyte surface glycopro-
tein. mAb to CD2 inhibit antigen-dependent helper T cell proliferation, IL-2
receptor expression, IL-2 secretion, cytolytic T lymphocyte-mediated killing,
and adhesion to target cells (2-8). We have interpreted these results to indicate
that CD2 is required for a T cell adhesion event that is critical to the initiation
of T lymphocyte functional responses (1). CD2 has also recently attracted
attention as a potential receptor or signal transducer for T cell activation via an
alternative pathway as opposed to the classical T cell receptor-CD3 activation
pathway (9-11).
LFA-3 is a widely distributed surface glycoprotein of 70,000 M,. when isolated
from B lymphoblastoid cells (2). mAb to LFA-3 inhibit a spectrum of cytolytic T
lymphocyte and helper T lymphocyte responses similar to that inhibited by CD2
mAb (2, 3). mAb to both molecules inhibit cytolytic T lymphocyte conjugate
formation (12).
CD2 and LFA-3 have been found to be components of a single functional
pathway, distinct from the LFA-1 pathway, in the adhesion of cytolytic T
lymphocytes to target cells (13). CD2 mAb inhibit cytolytic T lymphocyte-
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mediated killing by binding to the T cell, whereas LFA-3 mAb inhibit by binding
to the target cell (3, 13). Similarly, binding of thymocytes to thymic epithelial
cells requires CD2 on the thymocyte and LFA-3 on the thymic epithelial cell (14,
15). Subsequently we have found that purified CD2 binds to B lymphoblastoid
cells and that this binding is inhibited by LFA-3 mAb (16). Furthermore,
autologous rosetting between CD2} T lymphocytes and LFA-3'' human eryth-
rocytes is mediated by CD2 and LFA-3 (17; and Makgoba, M . W., S. Shaw, E.
A. Gugel, and M. E. Sanders, manuscript submitted for publication). These
results suggest that LFA-3 may be the cell surface ligand for CD2.
Characterization of the biological ligand for CD2 is of great importance. In
this study we have purified LFA-3 and functionally characterized its ability to
mediate T cell adhesion. We show that LFA-3 binds to CD2 on the surface of T
lymphocytes. Purified LFA-3 inhibits intercellular adhesion between T lympho-
cytes and erythrocytes, and mediates aggregation of T lymphocytes. Finally, we
show that LFA-3 reconstituted into artificial membranes can efficiently mediate
adhesion of human T lymphoblasts.
Materials and Methods
Cells.
￿
Human erythrocytes were stored in citrate/phosphate/dextrose/adenine of 4°C
for up to I wk before use. Peripheral blood mononuclear cellswere prepared by dextran
sedimentation of whole blood and then sedimentation on Ficoll-Hypaque (p = 1 .077;
Sigma Chemical Co., St. Louis, MO). To obtain peripheral blood lymphocytes, monocytes
were depleted from peripheral blood mononuclear cells by two incubations in complete
medium (RPMI 1640, 10% FCS) in tissue culture dishes at 2 x 107 cellsper 143-Cm2 plate
for 60 min followed by gentle removal ofnonadherent cells. T lymphoblasts wereprepared
by culturing peripheral blood mononuclear cells with 1 pg/ml Con A (Sigma Chemical
Co.) in RPMI-1640 20% FCS at 5 X 105 cells/ml for 4 d, followed by washing out Con A
and growing the cells in 1 ng/ml recombinant IL-2 for at least 3 d before use. The T
lymphoma cell line SKW3 was obtained from Dr. P. Cresswell, Duke University, Durham,
NC. The T lymphoma cell line, Jurkat, was obtained from Dr. M .-K. Ho, New England
Nuclear, Boston, MA. The B lymphoblastoid cell line JY was obtained from Dr. J.
Strominger, Dana-Farber Cancer Institute. Sheep erythrocytes were purchased from the
Colorado Serum Co., Denver, CO.
Monoclonal Antibodies. The mouse anti-human mAb TS2/9 (anti-LFA-3, IgGI),
TS2/18 (anti-CD2, IgG1), and TS 1/22 (anti-LFA-1, IgGI) (2) were used as purified IgG
or as dilutions of culture supernatants. TS2/9 mAb was purified from hybridoma culture
supernatants by (NH4)2SO4 precipitation and protein A-affinity chromatography. F(ab')2
of LFA-3 mAb were prepared by papain digestion of purified IgG (18). Nonbinding
control mAb was from culture supernatants of the P3X63 Ag8 IgGI-secreting myeloma.
Affinity columns.
￿
Purified IgG was coupled to Sepharose CL-4 B by a modification of
the method of Cuatrecasas (19). Washed Sepharose CL-4B (Pharmacia Fine Chemicals,
Upsala, Sweden) was activated with 40 mg/ml CNBr in I M Na2CO3 for 10 min on ice,
and then washed with distilled water and 0.1 mM HCI. The activated Sepharose was
filtered to a moist cake and added to purified antibody solution with 2-4 mg/ml IgG
(LFA-3 mAb or mouse IgG) in 0.05 M NaCl and 0.1 M NaHCO3, pH 8.4. The suspension
was mixed end-over-end for 20 h, and any remaining reactive groups were blocked by
addition of ethanolamine to 50 mM and incubation for 1 h. The supernatant was checked
for uncoupled antibody by measuring absorbance at 280 nm. Coupling was usually -90%.
The Sepharose was poured into a column and washed with one cycle of pH I I and pH 3
buffers (see below) before use for affinity chromatography.
Affinity Chromatography.
￿
LFA-3 was purified after solubilization with Triton X-100 by
affinity chromatography. All operations were done at 4° C. Outdated human erythrocytes
were obtained from the American Red Cross (Needham, MA). Cells from two units ofDUSTIN ET AL.
￿
679
whole blood were washed three times with PBS, pH 7.2. The packed cells were pelleted
to -500 ml. Another 500 ml of PBS pH 7.2 with 2% Triton X-100, I mM phenylmeth-
y1sulfonyl fluoride, 5 mM iodoacetamide, and 0.15 trypsin inhibitor units per milliliter
aprotinin was added to the red cell suspension while stirring. After I h the lysate was
centrifuged at 150,000gfor 2 h. The cleared lysate was passed over twocolumns in series
at a flow rate of 20 ml/h: first a mouse IgG-Sepharose column (2 ml at 2 mg/ml) to absorb
some contaminants and to filter out any particulate material, and second an LFA-3 mAb-
Sepharosecolumn (5-10 ml at 2 mg/ml). The LFA-3 mAb-Sepharose column was washed
with five column volumes of 50 mM sodium phosphate pH 7.2, 0.25 M NaCl, 0.1%
Triton X-100, then five column volumes of 20 mM triethylamine pH 11, 0.25 M NaCl,
0.1 % Triton X-100, andagain with two column volumesof thepH 7.2 buffer all at a flow
rate of 1 ml/min. Theremaining bound LFA-3 was then eluted with five column volumes
of 50 mM glycine HCI, pH 3, 0.25 M NaCI, 0.1% Triton X-100 at a flow rate of 20 ml/h.
LFA-3 generally eluted in one column volume and was neutralized by collection into 0.1
vol of I M Tris, pH 8.6, 0.1 % Triton X-100. In some preparations, contamination with
hemoglobin remained after one cycle ofaffinity chromatography. This couldbe removed
by loading the pooled LFA-3-containing fractions back onto the column and eluting with
pH 3 buffer after washing as above. The material obtained after two cycles of affinity
chromatography contained no contaminants detectable by SDS-PAGE andsilver staining.
When octyl-O-D-glucopyranoside (OG) (Calbiochem-Behring, San Diego, CA) was used to
elute LFA-3, all steps were the same until after the high-pH wash. The column was then
washed with five volumesof phosphate buffer, pH 7.2, 0.15 M NaCl, containing I% OG,
and the LFA-3 was eluted usingglycine buffer, pH 3, 0.15 M NaCl, 1% OG. The elution
profile was similar to that obtained with Triton X-100. LFA-3 purification could be
followed in a semiquantitative manner using a dot-blot assay (20) with 125I-LFA-3 mAb.
LFA-1 was purified from SKW3 cells by affinity chromatography on TS1/22 mAb-
Sepharose and eluted under the same conditions as LFA-3 (R. Larson, unpublished
observation). Protein concentrations were determined using the Coomassie blue dye-
binding assay (21) on acetone or ethanol (1 :5)-precipitated samples. Molar concentration
of LFA-3 and LFA-1 were calculated using M. of the polypeptide backbone of 25,000
(our unpublished data) and 210,000 (22), respectively.
LFA-3Iodination and BindingAssay.
￿
LFA-3 in 0.1% Triton X-100was dialyzed against
borate-buffered saline (pH 8.2) and labelled with
1251 using 1,3,4,6-tetrachloro-3a,6a-
diphenylglycoluril (Pierce Chemical Co., Rockford, IL) (23) and then dialyzed against
PBS. The purity of the iodinated LFA-3 was >90% by SDS-PAGE. Specific activity was
170 Ci/mmol. Bindingassays were done on 2 X 106 cells in 100 jl with an inputof 80,000
cpm in HBSS, 3% BSA, 10% FCS. After 60 min at 4°C the assay was terminated by
centrifugation through a 0.8-ml 15% BSA cushion. The supernatant was thoroughly
aspirated, and thetipof the centrifuge tube containing the pellet was cutoffandcounted.
mAb were added 15 min before addition of the "5I-LFA-3. All points were determined
in triplicate.
Flow Microfluorometry.
￿
TS2/18 and TS1/22 mAb in hybridoma culture supernatants
were titrated againstJurkat and peripheral blood lymphocytes to determine the lowest
concentration of mAb giving optimal staining. Nonbinding control mAb was used at 5
,ug/ml. All operations were carried out at VC. C. Cells (105) were incubated with purified
membrane protein or control buffer in 20 ul of HBSS, 15% BSA for 60 min. The 15%
BSA was included in this and .subsequent procedures to bind detergent, and has been
shown to protect cells from detergent-mediated damage (24). mAb were then added in
an additional 20 wl of the same buffer, and the suspension was incubated 15 min. The
cells were then washed threetimes andincubated with FITC-goatanti-mouse IgG(heavy
and light chain-specific; Zymed Laboratories, San Francisco, CA) for 30 min, washed
three times, fixed with 1% paraformaldehyde, and analyzed within 1 wk on a Coulter
epics V flow cytometer.
E Rosetting.
￿
Peripheral bloodlymphocytes or tumor cells (105) were mixed with sheep
E (107) in 10 ul of HBSS, 15% BSA. Membrane proteins or control buffers were added
in an additional 10 Fcl of HBSS, 15% BSA and the suspension was incubated 15-30 min680
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at 4 °C. All samples contained the same buffer and detergent concentration, even those
not receiving membrane protein. The cells were pelleted at 100 g for 10 min and held on
ice for 60 min. The pellets were gently resuspended and rosettes enumerated by counting
100 nucleated cells under phase illumination.
Liposome Preparation.
￿
Liposomes were prepared by OG dialysis (25). LFA-3 was eluted
from the affinity column in the presence of 34 mM (1%) OG instead of Triton X-100.
Lipids in chloroform were mixed at a ratio of egg phosphatidylcholine/cholesterol of 7:2.
The lipids (0.5 mg) were dried under a nitrogen stream and then placed under reduced
pressure for I h to remove residual chloroform. The lipid film was taken up in 1 ml of
0 .15 M NaCl, 0.05 M glycine, 0.1 M Tris, pH 8, with 20-30 pg of LFA-3 and 34 mM
OG and dialyzed against two changes of PBS, pH 7.2, and one of HBSS, 25 mM Hepes,
pH 7.2, over 36-48 h. As a control, human glycophorin (Sigma Chemical Co.) was also
reconstituted using the same procedure.
Preparation ofPlanar Membranes (26).
￿
Round glass coverslips (11 mm) were boiled in
1 :6 7X detergent (Linbro Chemical Co., Hamden, CT):water for 15 min. They were then
washed extensively over 24 h with distilled water, soaked overnight in 70% ethanol, and
allowed to dry. Drops (100 j1 of liposome suspension diluted to 0.1 to 0.2 mM lipid) were
placed in wells of 24-well cluster plates (Falcon Labware, Oxnard, CA). Glass coverslips
were gently placed on top of the lipid suspension drops and left for 20-30 min at ambient
temperature. The wells were then filled with media and the coverslips were carefully
flipped over to expose the fused lipidsurface. The well was washed three times with assay
medium (RPMI 1640, 10% FCS, 25 mM Hepes) to remove unfused liposomes. The lipid
surface was never exposed to air.
BindingAssay.
￿
T lymphoblasts or JY B lymphoblastoid cells were labelled with 5' Cr by
incubating 10' cells with 300 kCi of Na "Cr04 (New England Nuclear) in 3 ml of RPMI-
1640, 10% FCS for 90 min. The cellswere then washed three times with media containing
5 mM methyl-a-D-mannopyranoside, and twice with complete medium plus 25 mM Hepes,
pH 7 .4. Cells and planar membranes were treated with 20 kg/ml mAb for 15 min, and in
the case of pretreatment, washed before testing binding. Cells (2-5 X 105) were added
and the plates were centrifuged at 10 g for 1 min to facilitate even and rapid cell settling.
The plates were then either floated in a 37° C water bath for 15 min or placed on ice for
1 h. After the incubation the plates were washed with three changes of assay media, the
wells photographed, and the contents solubilized with 0.1 N NaOH and counted in a
gamma counter. Input counts were calculated to be the total input to the well multiplied
by the coverslip area per well area to determine the number of cells (cpm) falling on the
coverslip.
Photography.
￿
Photomicrographs were taken using a Nikon Diaphot inverted micro-
scope using bright-field or phase optics.
Results
We have tested human B lymphoblastoid cell lines, spleens from patients with
hairy cell leukemia, and erythrocytes (E) as sources for the purification of LFA-
3 . Fresh human E have ^-5,000 LFA-3 sites per cell (our unpublished observa-
tions). While B lymphoblastoid cell lines have ^-200,000 LFA-3 molecules per
cell (40-fold more than E), B lymphoblastoid cell lines contain only fourfold more
LFA-3 than E on the basis of packed cell volume. Due to their ready availability
in large quantity at low cost, erythrocytes were chosen for large-scale purification
of LFA-3 . We expected LFA-3 from erythrocytes to be fully functional, because
previous studies have shown that LFA-3 on the surface of intact E binds to
purified CD2 (17).
Packed E were solubilized with an equal volume of Triton X-100 lysis buffer,
and LFA-3 was isolated by immunoaffinity chromatography with LFA-3 mAb.
The affinity purification strategy took advantage of the unusual stability of theDUSTIN ET AL .
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FIGURE 1 .
￿
SDS-PAGE ofpurified LFA-3. Purified LFA-3 (0.3 jig in 10 pl) wasadded to 10
Al of 2x reducing sample buffer and run on SDS-8% polyacrylamide gel (43) . Protein was
visualized by silver staining (44).
antigen-antibody complex in alkaline pH (pH 11), which elutes many contami-
nating proteins . After the high-pH wash, LFA-3 was eluted at pH 3 . This
procedure allowed isolation of essentially pure LFA-3 from the affinity column
in a one-step isolation procedure (Fig . 1) . Site number estimates suggested that
erythrocytes from one unit of blood contain ^-500 ,ug of LFA-3 . Our recoveries
from three isolation procedures ranged from 100 to 150 jAg/unit . LFA-3 from
erythrocytes migrated on SDS-PAGE as a broad band of40,000-70,000 M, (Fig .
1) . This was somewhat lower than the 65,000-70,000 M,. observed for LFA-3
from B lymphoblastoid cells (2, 3), and was similar to LFA-3 isolated from the
epidermoid carcinoma cell line A431 and from spleens from patients with hairy-
cell leukemia (data not shown) .
We used the purified LFA-3 to test the hypothesis that it could bind to the
CD2 molecule on the surface of T lymphocytes . Purified, iodinated LFA-3
bound to the CD2' T lymphoma cell lines Jurkat and SKW3 (Table 1) . Binding
was specific, because it was inhibited 75-78% by excess unlabelled LFA-3, and
75%-76% by LFA-3 mAb . Strikingly, CD2 mAb inhibited binding of purified682
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TABLE I
Bindingof '251-LFA-3 to CD2 and CD2- Cells
After a 15-min preincubation with LFA-3 or control buffer, and with
specific or control mAb at 20 Pg/ml, cells (2 X 106) were incubated with
190 fmol (80,000 cpm) of '25I-LFA-3 in 100,ul of HBSS, 3% BSA, 10%
FCS. After 1 h, free and bound radioactivity were separated as described
in Materials and Methods. Each point is an average of triplicate determi-
nations and is representative of three experiments.
1251-LFA-3 to the CD2' cells by 78%. Purified LFA-3, LFA-3 mAb, CD2 mAb,
and the combination of LFA-3 mAb and CD2 mAb all inhibited to the same
extent. Nonspecific binding seen in the presence ofthese inhibitors was identical
to binding of ' 25I-LFA-3 to the CD2- B lymphoblastoid cell lineJY. These results
suggest that LFA-3 binds to the CD2 structure on T cells. The binding to JY
and nonspecific binding to CD2+ cells is probably due to some type ofnonspecific
association, which could involve insertion of the hydrophobic domain of the
LFA-3 molecule into the cell membrane (see below).
To further test the hypothesis that LFA-3 interacts with the CD2 molecule,
flow microfluorometry experiments were done to determine ifpreincubation of
cells with LFA-3 could inhibit the subsequent binding of the TS2/18 CD2 mAb
(Fig. 2). Fluorescence histograms show thatJurkat cells (Fig. 2a) and peripheral
blood T lymphocytes (Fig. 2b) preincubated with 140 nM LFA-3 bound 93%
and 98% less TS2/18 CD2 mAb, respectively, than cells preincubated with
control buffer. Half-maximal inhibition of CD2 mAb binding to Jurkat and
peripheral blood T lymphocytes was obtained at -4 and ^"1 nM LFA-3, respec-
tively (Fig. 2e). Binding of mAb to the LFA-1 surface molecule on either cell
type was not affected by preincubation with any concentration of LFA-3 (Fig. 2,
c, d, andf). As an additional control, pretreatment with purified LFA-1 mem-
brane protein (1000 nM) had noeffect on CD2 mAb binding (Fig. 2e). Inhibition
of 125I-LFA-3 binding by CD2 mAb and reciprocal inhibition of CD2 mAb
binding by purified LFA-3 demonstrates that the LFA-3 binds to the CD2
molecule, and further suggests that LFA-3 binds to CD2 at or near the TS2/18
epitope.
Purified LFA-3 was tested in functional assays to determine whether it could
inhibit rosetting of human T lymphocytes with human erythrocytes or sheep
erythrocytes. CD2 mAb inhibited rosetting of human T lymphocytes with both
sheep and human E (Table II) as previously reported (4, 17, and Makgoba et al.,
manuscript submitted for publication) . LFA-3 mAb reacts with human but not
sheep E, and inhibited rosetting with human but not sheep E (Table II), as
previously reported (17, and Makgoba et al., manuscript submitted for publica-
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FIGURE 2.
￿
Inhibition of CD2 mAb binding by purified LFA-3. a-d ; flow microfluorometry
histograms. Jurkat (a, c) or PBL (b, d) were incubated for 1 h at 4°C with control buffer or
140 nM LFA-3, stained with a nonbinding control mAb (dashed lines) or specific mAb (solid
lines) as indicated; and then stained with a FITC anti-Ig. The presence of LFA-3 in the
preincubation did not influence the intensity of the nonbinding control. e, f; concentration
dependence ofinhibition by LFA-3 of CD2 mAb binding (e)and control LFA-1 mAb binding
(f) toJurkat (open squares) or PBL (closed squares). As an additional controlJurkat (often circle)
and PBL (closed circle) were preincubated with the control membrane protein LFA-1 (1,000
nM), and then binding of CD2 mAb was determined (e).
' 10 ` 100 1000 10 100 1000
tion). However, since purified LFA-3 binds to CD2 on the T lymphocyte, we
predicted that it should inhibit rosetting with human T lymphocytes regardless
of the erythrocyte source. Purified LFA-3 (70 nM) completely abolished autolo-
gous rosetting~ of Jurkat T lymphoma cells with human erythrocytes (Table II).
Purified LFA-3 also completely inhibited rosetting ofJurkat cells and peripheral
blood T lymphocytes with sheep erythrocytes (Table II and Fig. 3, a-d). Inhi-
bition ofJurkat cell rosetting with sheep E was half-maximal at 7 nM LFA-3 (not
shown). Rosetting was not affected by incubation with control buffer or up to
1,000 nM LFA-1 (Table II and data not shown). Because LFA-3 mAb did not
inhibit rosetting with sheep E it was possible to test the specificity of the inhibition
by purified LFA-3 by adding excess LFA-3 mAb. LFA-3 mAb completely
neutralized the ability of purified LFA-3 to inhibit rosetting between human T
lymphocytes and sheep E (Table II).
In addition to inhibiting rosetting, purified LFA-3 caused aggregation of the
Jurkat cell line (Fig. 3 b). LFA-3 did not cause aggregation of erythrocytes (Fig.684 LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 3
TABLE 11
Rosetting ofErythrocytes by TLymphocytes
Suspensions of 105 T cells and 107 erythrocytes were incubated for 15
min at 4°C with 20,ug/ml mAb or purified proteins. The cells were then
pelleted, held on ice, and rosettes were enumerated by counting 100
nucleatedcells.
3b). We tested whether purified LFA-3 aggregated Jurkat cells by binding to
CD2. Experiments were done at 4°C; at this temperature, the CD2/LFA-3
adhesion pathway but not the LFA-1 pathway is operative (13). Suspensions of
Jurkat cells were treated with LFA-3 in the presence of control mAb or CD2
mAb at VC, C, pelleted, held on ice for 1 h, and then gently resuspended. In the
absence of exogenous LFA-3 there was a small but significant degree of aggre-
gation ofJurkat cells inwhich themajority ofcells werenotinvolvedin aggregates
(Fig. 3e). This aggregation was mediated by CD2 and the low quantity of
endogenous LFA-3 on Jurkat (7% ofexpression on B lymphoblastoid cell lines,
M. Plunkett and P. Selvaraj, unpublished data), because it was inhibited by CD2
mAb and LFA-3 mAb (not shown). Addition of exogenous LFA-3 greatly
enhanced Jurkat cell aggregation, to the point where almost all cells were in
large aggregates (Fig. 3f). This aggregation was completely inhibited by CD2
mAb and LFA-3 mAb (Fig. 3, g and h), suggesting that it is mediated by
interaction between the exogenous LFA-3 and cell surface CD2. Although the
physical form of LFA-3 that mediated Jurkat aggregation is not known, LFA-3
mayinsert intothe membrane byitshydrophobicdomain (seenonspecificbinding
in Table I) or LFA-3 may be present in a multimeric form in protein micelles.
LFA-3 normally functions as a protein anchored to the membrane by a
hydrophobic domain. To demonstrate adhesion function for thepurified protein
in lipid bilayers, LFA-3 was reconstituted into liposomes by octyl glucoside
dialysis, and the liposomes were fused onto glass coverslips (26) to allow obser-
vation ofcell binding. Based on the crossectional area oflipid molecules (60 A2
[27]), the ratio of lipid to protein (500:1), and assuming random inside/outside
orientation of LFA-3 in liposomes, the density of LFA-3 in these planar mem-
brane would be ^-7,000 molecules/um' . T lymphoblasts labelled with "Cr were
gently centrifuged onto the.planar membranes containing LFA-3, oras acontrol,
glycophorin. >90% of cells bound to the planar membrane containing LFA-3
(Fig. 4a and Table III) but only 2% bound to those containing human glyco-
phorin (Table III). Pretreatment ofthe T lymphoblasts with CD2 mAb (Fig. 4b)
or ofthe LFA-3-bearing planar bilayerwith LFA-3 mAb IgG orF(ab')2 fragments
Pretreatment
Rosettes with
human eryth-
rocytes and
Jurkat cells
Rosettes
sheep
cytes
Jurkat
with
erythro-
PBL
Control mAb 54 80 30
CD2 mAb 0 0 0
LFA-3 mAb 0 76 32
Purified LFA-3 0 0 0
Purified LFA-3 + LFA-3 mAb ND 74 36FIGURE 3.
￿
Purified LFA-3 inhibits E-rosetting and mediates aggregation of CD2' cells.
Jurkat cells (a, b) orPBL (c, d) were mixedwith sheep E, incubated in suspension with control
buffer (a, c), or purified LFA-3 (b, d) for 15 minandthen pelleted. After 1 h on ice the cells
were gently resuspended and photographed under bright-field illumination at X 500 (final) .
e-h; Jurkat cell aggregation . Jurkat cells (2 X 10') were incubated in suspension with control
buffer (e), 140nM purified LFA-3 (f), purified LFA-3+ 20 #g/ml CD2mAb (g) or purified
LFA-3 + 20 pg/ml LFA-3 mAb (h) . The cells were pelleted and left on ice for 1 h, gently
resuspended and photographed under bright-field illumination at 400x . All fields are repre-
sentative. Note that there aremore unaggregated jurkat cells in the absence of LFA-3 (e) than
in the presence ofLFA-3 (f).
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FIGURE 4 .
￿
Adhesion to planar membranes bearing LFA-3 . T lymphoblasts were added to
wells containing LFA-3-bearing planar membranes . T lymphoblasts were untreated (a) or
pretreated with 20 ug/ml CD2 mAb for 30 minandthen washed (b). After 15 min at 37°C,
the unbound cells were washed out and the wells photographed under phase illumination
(x 250, final) .
TABLE III
Adhesion ofCD2+ and CD2- Celts to LFA-3and
Glyeophorin-bearing Planar,
37'CTblasts
Control mAb
CD2mAb
CD2mAbpretreatment of cells
LFA-3 mAb
LFA-3 mAbpretreatment of planar
membranes
LFA-3 F(ab')p pretreatment o£planar
membranes
37°C JY
ControlmAb
LFA-3 mAb
Condition
Cell binding
(percent of input)
LFA-3
mem-
brane
Glyco-
phorin
mem-
brane
91 1.8
2.9 2.2
2.1 2.8
5.1 3.6
9.9 2.5
4.1 2.7
1 .2 3.9
1 .0 2.8
93
8.2
3.2
AftermAbpretreatment orin the continued presence ofspecific orcontrol
mAb, T lymphoblasts orJY cells (4-x 105) labeled with "Cr (50,0013 cpm)
were added to wells containing liposome-fused coverslips andcentrifuged
at 10gfor I minand then incubated at 37°C for 15 min or 4'C for I h .
Binding was determined as described in Materials and Methods. Results
are either from one experiment or averaged from points duplicated
betweentwo experiments.DUSTIN ET AL.
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inhibited >95% of the binding, essentially to the level of that seen with human
glycophorin-bearingplanar membranes (Table III). Resultswere similar whether
the cells were incubated on the planar membranes at 37'C for 15 min or at VC
for 1 h (Table III). The CD2- B lymphoblastoid cell line JY failed to bind to
LFA-3-bearing or control planar membranes (Table 111). These reconstitution
experiments show that purified LFA-3 functions as a ligand for CD2-mediated
T lymphocyte adhesion.
Discussion
Our results with purified LFA-3 show that it is a ligand for T cell adhesion
andthatadhesion is mediatedby itsinteraction withthe CD2 molecule. Iodinated
LFA-3 bound to CD2+ T lymphocytes in a specific manner as defined by the
ability of excess unlabeled LFA-3 to inhibit binding and the ability of LFA-3
mAbto inhibitbinding to the sameextent.This specific binding wasalso inhibited
by CD2 mAb, suggesting that LFA-3 bound to the CD2 structure on the T
lymphocyte surface. In the reciprocal experiment, purified LFA-3 was able to
inhibit the binding ofCD2 mAb to Tcells, suggesting that LFA-3 binds to a site
on CD2 at or near the TS2/18 epitope. Purified LFA-3 inhibited erythrocyte
rosetting by human T lymphocytes with both human and sheep erythrocytes.
This result suggests that binding of purified LFA-3 to T lymphocytes was
sufficient to interfere with the interaction of T cell CD2 with LFA-3 on the
human erythrocyte, and with its presumed homologue on sheep erythrocytes.
While LFA-3 inhibited rosetting, it enhanced aggregation ofthe CD2+Jurkat T
lymphoma cell line. This aggregation was a specific effect of exogenous LFA-3-
binding to cell surface CD2, because it was inhibited by CD2-mAb and LFA-3
mAb. This phenomenon provided evidence that LFA=3 can mediate intercellular
adhesion. To study adhesion in a more defined system, LFA-3 was reconstituted
into liposomes which were fused onto a glass surface to allow observation ofcell
binding. LFA-3 reconstituted intoplanar membranescouldmediate very efficient
CD2-dependent adhesion ofT lymphoblasts at both 37'C and VC. C. These results
clearly define LFA-3 as a cell surface ligand for the T lymphocyte function-
associated molecule CD2.
Previously (16, 17) we have shown that purified CD2 binds to LFA-3+ cells
and inhibits LFA-3 mAb binding. CD2 binds saturably to B lymphoblastoid cells
with a dissociation constant of 50 nM. Similarly, the half-maximal concentration
of CD2 required to inhibit LFA-3 mAb binding was 60 nM. Conversely, we have
found here that purified LFA-3 blocks binding ofCD2 mAb to both Jurkat cells
and peripheral blood T lymphocytes. The half-maximal concentration of LFA-3
required to inhibit CD2 mAb binding to peripheral blood T lymphocytes and
Jurkat cellswas 1 and 5 nM,respectively, which isanestimate oftheconcentration
of LFA-3 required to half saturate its binding sites or its dissociation constant.
Considering the ambiguities introduced by the presence of the hydrophobic
domains of each ofthese molecules, the estimates are in a similar range.
Purified LFA-3 was shown here to aggregate cells bearing CD2; similarly,
purified CD2 has been shown to aggregate cells bearing LFA-3 (16, 17). In both
cases, aggregation is mediated by interaction of CD2 with LFA-3, as shown by
mAb blocking. This is evidence that both proteins can directly mediate intercel-688
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lular adhesion. The ability of LFA-3 to mediate adhesion was most clearly
demonstrated here after reconstitution of LFA-3 into liposomes. Functional
studies involving cytolytic T lymphocyte conjugation with target cell have dem-
onstrated two distinct antigen-independent adhesion pathways, one dependent
on LFA-1, and another dependent on CD2 and LFA-3 (13). The CD2 and LFA-
3-dependent pathway, in contrast to the LFA-1 pathway, was not temperature-
dependent and did not require Mgt+. In agreement with these findings, we have
found that LFA-3 reconstituted in planar membranes mediates efficient binding
of T lymphoblasts both at 4°C and 37'C. Together with previous studies with
soluble CD2 and functional studies on the CD2/LFA-3 pathway in T lymphocyte
adhesion, the current findings provide strong evidence that the interaction
between LFA-3 and CD2 mediates cell-cell adhesion.
T lymphoma cell lines, T lymphoblasts, and thymocytes form stable rosettes
with human erythrocytes (28). In contrast, restingperipheral blood lymphocytes
fail to form rosettes with human erythrocytes (28-31). However, we have found
thatpurified LFA-3 binds to bothJurkat T lymphoma CD2 and peripheral blood
T lymphocyte CD2 with similar affinity. Our results suggest that the difference
in the ability ofactivated and restingTlymphocytes to form rosettes with human
erythrocytes must be due to differences in parameters other than LFA-3 binding
affinity. One relevant parameter is surface charge of cells, which is lower on
activated cells (32) and would result in lower electrostatic repulsion between
cells. Consistent with this view, peripheral blood T lymphocytes rosette with
human erythrocytes after reduction ofnet negative surface charge by neuramin-
idase treatment of human erythrocytes or of peripheral blood T lymphocytes
(33, 17). Along the same lines, we did not observe significant aggregation of
peripheral T lymphocytes after addition of purified LFA-3, while aggregation
ofJurkat cellswas reproducibly augmented. This again may be due to differences
in surface charge density, which would regulate the tendency of cells to come
into close contact. These same factors could be responsible for regulation of
CD2 dependent adhesion with other cell types.
LFA-3 is the first example ofa purified ligand molecule that has been directly
shown to mediate T lymphocyte adhesion. Several other T lymphocyte surface
antigens are thought to be involved in receptor-ligand type interactions with
structures on target cells or antigen-presenting cells. The T cell receptor is
thought to interact with nominal antigen physically associated with polymorphic
major histocompatability complex antigens (34). The interaction of the T cell
receptor with nominal antigen alone has been reported to have a dissociation
constant on the order of 10-5 M (35); the affinity of the same T cell receptors
for nominal antigen associated with MHC could be higher. The high-affinity
interaction of CD2 with LFA-3 may increase the efficiency ofcell-cell interaction
to a point where T cell receptor interaction with antigen can occur more
efficiently. This may be particularly important for low-affinity antigen receptors.
CD4 and CD8 have been suggested by functional data to interact with class II
and class I MHC antigens, respectively (36). However, attempts to demonstrate
an interaction between CD4 and class II molecules or CD8 and class I molecules
using either purified proteins or cells overproducing these proteins have been
unsuccessful thus far, using a variety of techniques (J. Strominger, personalcommunication). Lymphocyte function-associated antigen-1 (LFA-1) on T lym-
phocytes has also been suggested to interact with ligand molecu
(37) and the mouse (38), but no evidence for a direct interaction has
Recently, a molecule termed the TII target structure (TIITS) has been
identified on sheep erythrocytes (39). Antibodies to T11 TS inhibit rosetting of
human T cells with sheep erythrocytes. While the purified T11 TS has an M, of
42,000, which is somewhat lower than LFA-3 from human erythrocytes, it is
otherwise very similar in function and distribution to LFA-3 (40). Like purified
LFA-3, purified TI ITS blocks binding of CD2 mAb to human T lymphocytes
(39). These findings suggest that sheep T I ITS may be a functional homologue
of human LFA-3 (1).
It has been proposed that CD2 meth
activation, based on the ability of pairwise combinations of mAb to
epitopes to trigger T cell proliferation and cytotoxic function (9).
-3, the biological ligand of CD2, may be able to trigger T cell
exts. LFAQ blocks binding of the TS2/18 mAb
is with CD2 at or near this site which is designated
ape. Although binding to this
ep4ope by TS2/18 do, not lead to T cell activation, ligation with LFA-3 may
have more profound biological consequences. The question of trigg
lymphocyte proliferation or function via CD2 is particularly interesting
context of interactions of cells in the thymus (42). It has been
that thymocytes adhere to thymic epithelial cells via a CD2/LFA-3-dependent
adhesion pathway (14). This interaction may be of importance in regulating the
behavior of thymocyte populations that lack the T cell receptor-CD3 complex
and yet proliferate in the thymus (15, 42). In this report we have addressed
adhesion-related functions of purified LFA-3 . Further study is required to
establish a role of LFA-3 in T lymphocyte activation or triggering
suggest that
function, at
and therefore probab
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Summary
CD2 is a T lymphocyte glycoprotein that functions in adhesion of T lympho-
cytes and also as a putative receptor for activation signals. Functional data suggest
that LFA-3, a widely distributed cell surface glycoprotein, may be the biological
ligand of CD2 . We have purified LFA-3 from human erythrocytes and charac-
terized the purified protein functionally. LFA-3 bound specifically to CD2' cells,
and this binding was inhibited by CD2 mAb. Conversely, purified LFA-3 inhib-
ited binding of CD2 mAb to cells, and the concentration required for this effect
suggests that LFA-3 half-saturated CD2 at 1-5 nM LFA-3. Pu
inhibited rosetting of human and sheep erythrocytes with CD2'
cells and T lymphocytes, and mediated aggregation of a CD2' T lymphoma cell
line. Purified LFA-3 reconstituted into planar membranes mediated efficient
C132-dependent adhesion of T lymphoblasts. These data demonstrate that LFA-
3 is a ligand for CD2 and that LFA-3 can mediate T lymphocyte adhesion .
y of T cell
main CD2
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